As previously presented, gedatolisib + palbociclib + fulvestrant ('gedatolisib triplet”) and gedatolisib + fulvestrant ('gedatolisib doublet”) reduced the risk of disease progression or death versus ...

Statista, a global data company that publishes insights for 170 industries, projects four cancer therapies will be among the top 10 best-selling pharmaceutical products in the U.S. this year.  The ...

Obesity is now linked to at least 13 types of cancer, making it one of the most preventable cancer risk factors in the United ...

Neuroscientists at King's College London have pinpointed a mechanism behind the increased neural connectivity observed in the very early stages of Alzheimer's disease. Published in Translational ...

Are time commitments related to cancer care toxic? Depends on who you ask.The term “time toxicity” has become cancer jargon over the past few years, sparking research into how much time patients spend ...

Dr. Hope Rugo explains how antibody-drug conjugates like Datroway and Trodelvy are shifting the treatment landscape for ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...

The drug is sometimes prescribed to certain at-risk people—but what does the science say?

Roche shares have dropped after its oral breast cancer drug giredestrant failed to show benefits in a key phase III clinical ...

Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its promising drug candidate ...